Issues lobbied + lobbyists (3)
HCR — Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, reintroduction of the PASTEUR Act, CMS practice expense final rule, draft legislation to carve out ID physicians from CMS practice expense final rule, ioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352, not yet introduced in the Senate, upcoming legislation on CMS practice expense cuts.
Lobbyists:- AMANDA JEZEK — covered position: S.V.P of Public Policy & Government
- LISA COX — covered position: Director of Government Relations
- AMANDA WOODSON — covered position: Manager, Government Relations [new]
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE
MED — Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352 119th Congress) Senate PASTEUR Act not yet introduced in 119th Congress, Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445)not yet introduced in Senate, SUPERBUGS Act, H.R.7879, 119th Congress.
Lobbyists:- AMANDA JEZEK — covered position: S.V.P Public Policy & Government Relations
- LISA COX — covered position: Director of Government Relations
- AMANDA WOODSON — covered position: Manager, Government Relations [new]
Government entities lobbied: Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE
BUD — Budget/Appropriations
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Center for Disease Control and Prevention, National Institutes of Health, Health Resources Services Administration, Food and Drug and Administration, and global programs for various infectious diseases related issues. Emergency supplemental funding support to address the COVID-19 pandemic and the monkeypox outbreak, FY2025 President's Budget, FY2025 Labor, Health, and Human Services Appropriations bills, FY2025 State and Foreign Operations Appropriations bills, FY2026 Labor, Health, and Human Services Appropriations bills, FY2026 State and Foreign Operations Appropriations bills FY2026 President's Budget, avian flu outbreak, Administration executive orders regarding HHS, CDC, NIH, HRSA, FDA, and USAID, FY2025 recissions package, FY2026 House and Senate Continuing Resolutions and related legislation, federal government shutdown-related legislation and Administrative actions, final FY2026 House and Senate Labor, Health and Human Services and State and Foreign Operations appropriations bills, FY2027 President's budget proposal, FY2027 House and Senate Labor, Health, and Human Services and State and Foreign Operations appropriations bill.
Lobbyists:- AMANDA JEZEK — covered position: S.V.P of Public Policy and Government Relations
- LISA COX — covered position: Director of Government Relations
- AMANDA WOODSON — covered position: Manager, Government Relations [new]
Government entities lobbied: Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Management & Budget (OMB); SENATE